Screener
NovoCure NVCR Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from NovoCure’s reported figures.
Based on trailing twelve months.
The source filing: NovoCure’s 10-Q, filed July 23, 2026. Open the filing →
- Filed
- Jul 23, 2026, 6:59 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001645113-26-000062
FAQ
- What is NovoCure's return on equity?
- NovoCure (NVCR) reported return on equity of -43.2% in Q2 2026.
- How has NovoCure's return on equity changed year-over-year?
- NovoCure's return on equity increased by 10.1% year-over-year, from -48.1% to -43.2%.
- What is the long-term trend for NovoCure's return on equity?
- Over 5 years (2020 to 2025), NovoCure's return on equity has grown at a 46.8% compound annual growth rate (CAGR), from 5.7% to -38.9%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about NovoCure's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude